| 摘要 |
Disclosed is a use of an antibody composition in the manufacture of a medicament for treating cancer in a subject that has been subjected to a prior treatment regimen using an anti-human EGFR antibody, said antibody composition comprising a first anti-human EGFR antibody molecule and a second anti-human EGFR antibody molecule distinct from the first molecule, a) wherein the first anti-human EGFR antibody molecule is selected from the group consisting of: i) an antibody whose VL comprises amino acids 3-109 of SEQ ID NO: 72 and whose VH comprises amino acids 3-124 of SEQ ID NO: 40; ii) an antibody having the light chain CDR1, CDR2, and CDR3 in SEQ ID NO: 72 and the heavy chain CDR1, CDR2, and CDR3 in SEQ ID NO: 40; and iii) an antibody whose light chain comprises amino acids 3-216 of SEQ ID NO: 72, and whose heavy chain has a VH comprising amino acids 3-124 of SEQ ID NO: 40 and a constant region comprising the amino acid sequence of SEQ ID NO: 91; and b) wherein the second anti-human EGFR antibody molecule is selected from the group consisting of: i) an antibody whose VL comprises amino acids 3-114 of SEQ ID NO: 73 and whose VH comprises amino acids 3-120 of SEQ ID NO: 41; ii) an antibody having the light chain CDR1, CDR2 and CDR3 in SEQ ID NO: 73 and the heavy chain CDR1, CDR2, and CDR3 in SEQ ID NO: 41; and iii) an antibody whose light chain comprises amino acids 3-221 of SEQ ID NO: 73, and whose heavy chain has a VH comprising amino acids 3-120 of SEQ ID NO: 41 and a constant region comprising the amino acid sequence of SEQ ID NO: 91. Note - the sequences are as disclosed in the specification. |
